Sign In
Buy AMGN
$338.22
+9.96 (+3.03%)
At Close: Jun 03, 2026
This GLP-1 Stock's Bad News Could Be a Big Win for Eli Lilly and Novo Nordisk
09:14pm, Tuesday, 01'st Jul 2025
There are a lot of healthcare companies that are investing in GLP-1 weight loss drugs. Today, the leaders in that space are Eli Lilly and Novo Nordisk.
Trading Rotation Kicks Off 2nd Half of 2025
07:11pm, Tuesday, 01'st Jul 2025
Tech stocks lagged after a very strong first half of the year, while healthcare led the way.
Why Amgen Stock Popped by 4% Today
06:55pm, Tuesday, 01'st Jul 2025
Following quite encouraging news from the laboratory on Monday, Amgen (AMGN 4.07%) was something of a stock market favorite the following day. Its shares closed the trading session more than 4% higher
Investors Heavily Search Amgen Inc. (AMGN): Here is What You Need to Know
10:01am, Tuesday, 01'st Jul 2025
Amgen (AMGN) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Amgen's gastric cancer drug meets late-stage trial goal
09:10am, Monday, 30'th Jun 2025
Amgen said on Monday its experimental cancer therapy, when combined with chemotherapy, met the main goal in a late-stage trial.
At an Interim Analysis, Bemarituzumab Plus Chemotherapy Significantly Improved Overall Survival in People With FGFR2b Overexpression Compared to Chemotherapy Alone THOUSAND OAKS, Calif. , June 30, 202
2 Dividend Stocks to Buy on the Dip and Hold Forever
05:05am, Monday, 30'th Jun 2025
Over the past year, Apple (AAPL 0.04%) and Amgen (AMGN -0.69%), two well-established companies that are part of the iconic Dow Jones Industrial Average, have faced significant headwinds. Apple is stru
Amgen Looks to Take Share of Booming Obesity Space: Will It Succeed?
11:11am, Friday, 27'th Jun 2025
Amgen aims to challenge obesity drug leaders with MariTide, a potential monthly treatment now in late-stage trials.
Here's Why Amgen (AMGN) is a Strong Growth Stock
10:50am, Friday, 27'th Jun 2025
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Here's Why Amgen (AMGN) is a Strong Value Stock
10:46am, Wednesday, 25'th Jun 2025
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Analyst Views Mixed As Amgen's Weight Loss/Diabetes Drug MariTide Shows Promise But Has Dose Issues
02:54pm, Tuesday, 24'th Jun 2025
Amgen Inc AMGN announced on Monday the full results from Part 1 of the Phase 2 study of MariTide (maridebart cafraglutide, formerly AMG 133), a long-acting, peptide-antibody conjugate subcutaneously a
What's Happening With Amgen Stock?
09:25am, Tuesday, 24'th Jun 2025
Amgen stock (NASDAQ:AMGN) fell 6% on Monday, June 23, 2025, after mid-stage clinical trial results for its long-acting experimental obesity drug, MariTide, revealed a need for a low starting dose to m
Amgen Inc. (AMGN) Presents at Special Call (IR Call) Conference Transcript
01:44am, Tuesday, 24'th Jun 2025
Amgen Inc. (NASDAQ:AMGN ) Special Call (IR Call) Conference June 23, 2025 5:30 PM ET Company Participants Justin Claeys - Vice President of Investor Relations James Bradner - Executive Vice President
Amgen (AMGN) Stock Slides as Market Rises: Facts to Know Before You Trade
07:01pm, Monday, 23'rd Jun 2025
In the latest trading session, Amgen (AMGN) closed at $272.44, marking a -5.84% move from the previous day.
Pharma companies need to beef up M&A right now, says Mizuho's Jared Holz
06:10pm, Monday, 23'rd Jun 2025
Jared Holxz, Mizuho, joins 'Fast Money' to talk competition in the obesity drug space.
